Therefore, our work indicates that PKC inhibitors that target parasite development in the mammalian host could simultaneously decrease malaria transmission by the mosquito vector, providing an extended activity that has been recently recognized as a critical need for anti-malarial drugs [75]. This evidence concerns the gene PRRT2 and malaria.